by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer’s Disease in Down Syndrome (DS-AD) remains challenging in clinical settings. This...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Pathological and neuroimaging alterations in the cerebellum of Alzheimer’s disease (AD) patients have been documented. However, the role of cerebellum-derived radiomic and structural connectome modeling in the prediction of AD progression...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non-Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Development of Alzheimer’s disease (AD) pathology in Down’s syndrome (DS) occurs within a compressed timeline compared to sporadic or other genetic forms of AD. METHODS Plasma glial fibrillary acidic protein (GFAP) and plasma pTau-217...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract White matter hyperintensities (WMH) and infarcts found on magnetic resonance imaging (MR infarcts) are common biomarkers of cerebrovascular disease. In this review, we summarize the methods, publications, and conclusions stemming from the Alzheimer’s...
